Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4852868
Max Phase: Preclinical
Molecular Formula: C56H75F15N14O17
Molecular Weight: 931.16
Molecule Type: Unknown
Associated Items:
ID: ALA4852868
Max Phase: Preclinical
Molecular Formula: C56H75F15N14O17
Molecular Weight: 931.16
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)N[C@H](CCCN)C(=O)NCCN1CCN(CCCC2CCN(CC(=O)N3c4ccccc4NC(=O)c4ccccc43)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C46H70N14O7.5C2HF3O2/c1-31(61)53-45(67)37(29-40(48)62)56-44(66)36(13-7-19-52-46(49)50)54-35(12-6-18-47)43(65)51-20-24-58-27-25-57(26-28-58)21-8-9-32-16-22-59(23-17-32)30-41(63)60-38-14-4-2-10-33(38)42(64)55-34-11-3-5-15-39(34)60;5*3-2(4,5)1(6)7/h2-5,10-11,14-15,32,35-37,54H,6-9,12-13,16-30,47H2,1H3,(H2,48,62)(H,51,65)(H,55,64)(H,56,66)(H4,49,50,52)(H,53,61,67);5*(H,6,7)/t35-,36+,37+;;;;;/m1...../s1
Standard InChI Key: DFNBPGJCOZOPTQ-JKGMKDQCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 931.16 | Molecular Weight (Monoisotopic): 930.5552 | AlogP: -0.51 | #Rotatable Bonds: 24 |
Polar Surface Area: 306.54 | Molecular Species: BASE | HBA: 13 | HBD: 10 |
#RO5 Violations: 3 | HBA (Lipinski): 21 | HBD (Lipinski): 13 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.56 | CX Basic pKa: 11.97 | CX LogP: -2.97 | CX LogD: -8.47 |
Aromatic Rings: 2 | Heavy Atoms: 67 | QED Weighted: 0.04 | Np Likeness Score: -0.29 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):